Nektar Therapeutics (NKTR) Asset Writedowns and Impairment (2012 - 2025)

Nektar Therapeutics' Asset Writedowns and Impairment history runs 5 years deep, the most recent figure standing at $4.4 million for Q4 2025.

• In Q4 2025, Asset Writedowns and Impairment changed N/A year-over-year to $4.4 million; the TTM figure through Dec 2025 stood at $4.4 million (down 46.68% YoY), while the FY2025 annual figure was $4.4 million, down 46.68% from the prior year.
• Asset Writedowns and Impairment was $4.4 million for Q4 2025 at Nektar Therapeutics, down from $8.3 million in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $57.3 million in Q2 2022 to a low of -$1000.0 in Q4 2023.
• Historically, Asset Writedowns and Impairment has averaged $12.0 million across 4 years, with a median of $7.2 million in 2022.
• Biggest YoY gain for Asset Writedowns and Impairment was 780.58% in 2023; the steepest drop was 100.01% in 2023.
• A 4-year view of Asset Writedowns and Impairment shows it stood at $7.2 million in 2022, then plunged by 100.01% to -$1000.0 in 2023, then jumped by 833000.0% to $8.3 million in 2024, then sank by 46.68% to $4.4 million in 2025.
• The last three Asset Writedowns and Impairment figures came in at $4.4 million (Q4 2025), $8.3 million (Q2 2024), and -$1000.0 (Q4 2023), per Business Quant data.